Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ting Xu Ph.D. | Founder, Executive Chairman & CEO | 7.23M | -- | 1973 |
| Ms. Yang Liu | VP of Corporate Operations & Executive Director | 3.12M | -- | 1972 |
| Mr. Yumin Wan | Vice President of Government Affairs & Public Relations | -- | -- | 1972 |
| Dr. Mike Liu M.B.A., Ph.D. | Senior Vice President of Business Development | -- | -- | 1966 |
| Mr. Jing Han | Chief Commercial Officer | -- | -- | 1973 |
| Ms. Lok Yee Chan A.C.I.S., A.C.S. | Joint Company Secretary | -- | -- | 1990 |
| Ms. Qiulan Cheng | Joint Company Secretary | -- | -- | -- |
Alphamab Oncology
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 420
Description
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase III clinical trials for treatment of HER2-positive breast cancer; and phase I and II clinical trial treatment of heavily pre-treated HER2 cancers, as well as Phase II clinical trial to treat unreselectable or metastatic HER2-positive solid tumors. The company's product pipeline also comprises KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for neoadjuvant/adjuvant treatment of non-small cell lung cancer and endometrial cancer; and KN019, a CTLA-4-based immunosuppressant fusion protein, for auto-immune diseases and oncology treatment-induced immune disorders. In addition, its product pipeline also includes KN052, a PD-L1/OX40 bispecific antibody that prevents the immune escape of tumor cells; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in phase I/II clinical trial for the treatment of HER2-expressing advanced or metastatic solid tumors; and JSKN033, a subcutaneous antibody-drug conjugate to treat HER2-expressing advanced or metastatic solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Corporate Governance
Upcoming Events
March 25, 2025 at 12:16 PM UTC
Alphamab Oncology Earnings Date
Recent Events
Recent Events Information Not Available